Considering that diseases such as ATR-related Seckel syndrome and Werner syndrome are associated with the abnormal activation of ATR and the downstream p38-MAPK singling pathway [41, 42], it is therefore suggested that NOL12 may serve as a potential therapeutic target for diseases related to abnormal ATR activation. This evidence concerns the gene ATR and Werner syndrome.